Scienture Holdings
SCNX on Nasdaq. Pharmaceutical preparations. Market value $132m.
Price checks use the past 12 months to June 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Cash flow or capital spending isn't reported, so free cash flow is unknown.
Should I look at this?
Look carefully before going further
Why it could be worth it
Read the warning sign in its own filings
This is not advice. Check the numbers below.
We could not compute this from the filings.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: not known. Price score: 16 of 100. Our list needs 70 on quality and 60 on price.
$3.36 a share, 5% above its 1-year low
Over the past year the price has ranged from $3.21 to $65.00.
Pays no dividend
Price from Friday’s close (16 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $10m | $10m | $1m | $136,643 | $431,609 |
| Operating margin | |||||
| Operating margin | -53.5% | -28.4% | -322.4% | -10758.7% | -9867.9% |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | 0.04 | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.01bn | 0.00bn | 0.01bn | 0.04bn | 0.04bn |
Health checks
- Free cash flow positive0 of 2 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)4 of 8 checks we could run
- Profit backed by cash (accruals)No
- DebtUnknown
- Revenue growth, five yearsShrinking, 52.1% a year
- Buying back its own sharesNo, 341% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- A loss of $3 million, compared with a loss of $7 million a year ago.
- It loses 4879 cents on each $1 of sales, compared with 12825 cents a year earlier.
- 180% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in 3 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $64,861 |
| December 2024 | $53,083 |
| March 2025 | $10,258 |
| June 2025 | $0 |
| September 2025 | $590,050 |
| December 2025 | -$168,699 |
| March 2026 | $56,325 |
| June 2026 | $343,639 |
| Quarter to | Amount |
|---|---|
| September 2024 | -$3m |
| December 2024 | -$7m |
| March 2025 | -$3m |
| June 2025 | -$7m |
| September 2025 | -$4m |
| December 2025 | -$28m |
| March 2026 | -$3m |
| June 2026 | -$3m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 30 March 2026
- Next quarterly (estimated, 10-Q)
- 12 November 2026
Who owns it
None of the long-term investors we follow own it. 16 funds in all.
Largest holders overall
- Vanguard Capital Management$178,637Added
- Geode Capital Management$117,237Cut
- Susquehanna International Group, LLP$82,291New
- Vanguard Fiduciary Trust$69,321
- Citadel Advisors$57,699New
- HRT Financial LP$46,000New
- XTX Topco$36,680Added
- Northern Trust$30,662Added
- UBS Group AG$30,070Cut
- Jane Street Group$26,506Added
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
No one has reported a stake above 5% since December 2024.
- Scoggin Management LPPassive investorSold down below 5%Since 14 August 2025
- L1 Capital Global Opportunities Master Fund, Ltd.Passive investorSold down below 5%Since 14 November 2025
| Holder | Stake | Since | |
|---|---|---|---|
Scoggin Management LP Passive investor | Sold down below 5% | 14 August 2025 | |
L1 Capital Global Opportunities Master Fund, Ltd. Passive investor | Sold down below 5% | 14 November 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought or sold on the open market in the last 12 months.
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Scienture Holdings’ filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 30 Mar 2026, plus the 10-Q filed 13 Aug 2026 and 8 later 8-Ks.
Weak checks on its own accounts
SeriousThe company said its checks on its own accounts did not work at year end. Mistakes could slip into the numbers.
“Based on our assessment, management concluded that the Company’s internal controls over financial reporting were not effective as of December 31, 2025, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP.”
Show the full paragraph
Management’s Report on Internal Control Over Financial Reporting Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, but because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. The Company’s internal control over financial reporting includes those policies and procedures that are designed to: ● | pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; ● | provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and ● | provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements. Management conducted an assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2025. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control — Integrated Framework (2013). Based on our assessment, management concluded that the Company’s internal controls over financial reporting were not effective as of December 31, 2025, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. Specifically, management’s determination was based on the following material weaknesses which existed as of December 31, 2025: ● | Financial Reporting Systems: The Company did not maintain a fully integrated financial consolidation and reporting system throughout the period and as a result, extensive manual analysis, reconciliation and adjustments were required in order to produce financial statements for external reporting purposes. ● | Segregation of Duties: The Company does not currently have a sufficient complement of technical accounting and external reporting personnel commensurate to support standalone external financial reporting under public company or SEC requirements. Specifically, the Company did not effectively segregate certain accounting duties due to the small size of its accounting staff and maintain a sufficient number of adequately trained personnel necessary to anticipate and identify risks critical to financial reporting and the closing process. In addition, there were inadequate reviews and approvals by the Company’s personnel of certain reconciliations and other processes in day-to-day operations due to the lack of a full complement of accounting staff.
From the 10-K filed 30 March 2026, Item 9A. Controls and Procedures (table). Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- Sales have shrunk: 52.1% a year.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.